This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., NJ, USA.
Reference
Skinner KE, et al. Assessing direct costs of treating metastatic triple-negative breast cancer in the USA. Journal of Comparative Effectiveness Research : 10 Nov 2020. Available from: URL: https://doi.org/10.2217/cer-2020-0213
Rights and permissions
About this article
Cite this article
Hospitalisation drives cost to treat metastatic triple-negative breast cancer. PharmacoEcon Outcomes News 867, 17 (2020). https://doi.org/10.1007/s40274-020-7314-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7314-3